Valuation : GlaxoSmithKline Pharmaceuticals Limited

Market Cap 50TCr 529.67Cr 455.51Cr 428.43Cr 391.09Cr 731.43Cr 733.8Cr 5.08TCr 1.96TCr 26TCr 1.99TCr 1.95TCr 82TCr P/E 2027 *
43x
P/E 2028 * 37.3x
Enterprise Value 50TCr 529.67Cr 455.51Cr 428.43Cr 391.09Cr 731.43Cr 733.8Cr 5.08TCr 1.96TCr 26TCr 1.99TCr 1.95TCr 82TCr EV / Sales 2027 *
11.8x
EV / Sales 2028 * 10.6x
Free-Float
-
Yield 2027 *
1%
Yield 2028 * 1%

Last Transcript : GlaxoSmithKline Pharmaceuticals Limited

1 day-0.06%
1 week-3.15%
Current month-3.15%
1 month+14.03%
3 months+36.50%
6 months+17.68%
Current year+19.67%
1 week 2,908.75
Extreme 2908.75
3,074
1 month 2,577.9
Extreme 2577.9
3,121.1
Current year 2,088
Extreme 2088
3,121.1
1 year 2,088
Extreme 2088
3,121.1
3 years 1,387.9
Extreme 1387.9
3,515.95
5 years 1,228
Extreme 1228
3,515.95
10 years 1,020
Extreme 1020
3,515.95
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2022
Director of Finance/CFO - 01/04/2026
Chief Tech/Sci/R&D Officer - 08/07/2024
Director TitleAgeSince
Chairman 73 01/04/2019
Director/Board Member 59 18/05/2020
Director/Board Member 67 16/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-0.06%-3.15%+6.74%+104.65% 530.85Cr
-0.88%-0.64%+58.05%+100.51% 1,02400Cr
-1.15%+3.53%+54.25%+71.99% 66TCr
-1.44%+0.02%+20.65%+72.22% 45TCr
-0.95%+0.23%+28.96%+37.78% 35TCr
-3.18%+1.78%+20.66%+41.55% 30TCr
+0.30%+0.60%-0.40%+11.25% 25TCr
-1.55%+1.71%+54.15%+71.87% 24TCr
+0.02%+2.24%-14.59%-55.80% 21TCr
-0.15%+3.18%+31.24%+104.21% 19TCr
Average -0.90%+0.69%+25.97%+56.02% 36.84TCr
Weighted average by Cap. -1.07%+0.63%+37.16%+64.56%

Financials

2027 *2028 *
Net sales 4.26TCr 45Cr 39Cr 36Cr 33Cr 62Cr 62Cr 431.68Cr 166.86Cr 2.18TCr 169.03Cr 165.34Cr 6.94TCr 4.72TCr 50Cr 43Cr 40Cr 37Cr 69Cr 69Cr 479.06Cr 185.17Cr 2.42TCr 187.59Cr 183.49Cr 7.71TCr
Net income 1.17TCr 12Cr 11Cr 9.97Cr 9.1Cr 17Cr 17Cr 118.18Cr 46Cr 596.82Cr 46Cr 45Cr 1.9TCr 1.34TCr 14Cr 12Cr 11Cr 10Cr 20Cr 20Cr 136.07Cr 53Cr 687.14Cr 53Cr 52Cr 2.19TCr
Net Debt - -
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
07/26/07 ₹2,956.95 -0.06% 24,980
04/26/04 ₹2,958.60 +0.79% 1,734
03/26/03 ₹2,935.35 -0.38% 2,151
02/26/02 ₹2,946.60 -1.61% 3,317
01/26/01 ₹2,994.70 -1.91% 2,956
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,956.95INR
Average target price
3,081.00INR
Spread / Average Target
+4.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 500660 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!